PharmaEssentia is again attempting to list BESREMi, its new drug for polycythemia vera (PV), for reimbursement in Korea.

Dailypharm’s coverage found that the Taiwanese pharmaceutical company PharmaEssentia has recently resubmitted an application for the reimbursement of BESREMi (Ropeginterferon alfa-2b) in Korea.

The company had submitted an application for the reimbursement of its drug in March last year as a treatment for patients with polycythemia vera resistant or intolerant to hydroxyurea but failed to clear the hurdle of Korea’s Health Insurance Review and Assessment Service’s Cancer Disease Review Committee in July of the same year.

At the time, the CDDC determin